Long-Term Outcomes Among Two-Year Survivors of Autologous Hematopoietic Cell Transplant for Hodgkin and Diffuse Large B-Cell Lymphoma

BACKGROUND: Autologous hematopoietic cell transplant (autoHCT) is a standard therapy for relapsed Hodgkin lymphoma (cHL) and diffuse large B-cell lymphoma (DLBCL); however, long-term outcomes are not well described. METHODS: We analyzed survival, non-relapse mortality, late effects and subsequent ma...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Cancer
Glavni autori: Myers, Regina, Hill, Brian T., Shaw, Bronwen E., Kim, Soyoung, Millard, Heather R., Battiwalla, Minoo, Majhail, Navneet, Buchbinder, David, Lazarus, Hillard M., Savani, Bipin N., Flowers, Mary E.D., D’Souza, Anita, Ehrdardt, Matt, Langston, Amelia, Yared, Jean, Hayashi, Robert J., Daly, Andrew, Olsson, Richard F., Inamoto, Yoshi, Malone, Adriana K., DeFilipp, Zachariah, Margossian, Steven, Warwick, Anne, Jaglowski, Samantha, Beitinjaneh, Amer, Fung, Henry, Kasow, Kimberly, Marks, David I., Reynolds, Jana, Stockerl-Goldstein, Keith, Wirk, Baldeep M., Wood, William, Hamadani, Mehdi, Satwani, Prakash
Format: Artigo
Jezik:Inglês
Izdano: 2017
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5871233/
https://ncbi.nlm.nih.gov/pubmed/29125192
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.31114
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items